“…Injectable biomaterials have shown promise in pre-clinical studies resulting in a range of improvements including increased ventricular wall thickness (Christman et al, 2004; Landa et al, 2008; Plotkin et al, 2014; Kadner et al, 2012; Dobner et al, 2009; Sabbah et al, 2013; Leor et al, 2009), increased scar thickness (Landa et al, 2008; Kadner et al, 2012; Leor et al, 2009), higher ejection fractions (Christman et al, 2004; Landa et al, 2008; Plotkin et al, 2014; Kadner et al, 2012; Sabbah et al, 2013) and decreased ventricular dilation (Christman et al, 2004; Landa et al, 2008; Plotkin et al, 2014; Kadner et al, 2012; Dobner et al, 2009; Sabbah et al, 2013; Leor et al, 2009). Alginate injections are known to have nonthrombogenic properties (Lee and Mooney, 2001; Cabrales et al, 2005) in addition to mitigating the effects of adverse ventricular remodelling following MI, which makes them a particularly viable potential therapy.…”